BioSpace News Archive

Protalix BioTherapeutics, Inc. reported financial results for the second quarter ended June 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced its financial results for the second quarter of 2023 and provided a corporate update.

Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, announced the appointment of Deanna M. Petersen, MBA, as its Chief Business Officer.

Provectus announced that preclinical data from ongoing research on investigational cancer immunotherapy PV-10 as an immune vaccine adjuvant will be presented on a poster presentation at the Society for Immunotherapy of Cancer 2023 annual meeting to be held in San Diego, CA from November 1-5.

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, announced the completion of the clinical phase of the Phase 2 proof-of-concept PREVAIL study of TNX-102 SL as a potential treatment for fibromyalgia-type Long COVID.

Ikena Oncology, Inc. and Pionyr Immunotherapeutics, Inc. announced the closing of Ikena’s acquisition of Pionyr in an all-stock transaction.

Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the second quarter ended June 30, 2023, and provided business highlights.

Praxis Precision Medicines, Inc. announced the results from an analysis of EEG activity for subjects in the recent Phase 1 study that demonstrated pharmacodynamic activity across all dose levels for study subjects who received PRAX-628 at first administration as compared with subjects who received placebo.

Gritstone bio, Inc. today announced that the company has joined the ctMoniTR Project , a collaborative research initiative providing foundational evidence to inform future use of change in circulating tumor DNA (ctDNA) as an early indicator of long-term clinical benefit from therapeutics in cancer patients.

Marker Therapeutics, Inc. today announced non-clinical data of its lead multi-tumor-associated antigen (multiTAA)-specific T cell product candidate, MT-401, in an Off-the-Shelf (OTS) setting and provided an update on clinical readiness for the OTS program.